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Background: The objective of this randomized clinical study was to evaluate the effect of systemic administration 
of moxifloxacin compared to amoxicillin and metronidazole, combined with non-surgical treatment in patients 
with generalized aggressive periodontitis (GAgP) in a 6-month follow-up.
Material and Methods: A total of 39 systemically healthy patients with GAgP were evaluated in this randomized 
clinical trial. Periodontal parameters were recorded at the baseline during the 1st, 3rd and 6th month. Patients re-
ceived either 400 mg of moxifloxacin per os once daily or 500 mg of metronidazole and 500 mg amoxicillin per 
os three times daily for 7 days consecutively. 
Results: No significant differences between groups were found in any parameters at the baseline. Both groups led 
to a statistically significant decrease in all clinical periodontal parameters compared to the baseline (PI, p<0.001 
and GI, PD, BOP, CAL, p<0.01). There were no differences between the 1st and 3rd months or the 3rd and 6th months 
for clinical parameters in the groups. Also, no intergroup difference was observed in any parameters at any time, 
except the gingival index at 6th months. 
Conclusions: Systemic administration of moxifloxacin as an adjunct to non-surgical treatment significantly im-
proves clinical outcomes and provides comparable clinical improvement with less adverse events to that of com-
bination of amoxicillin and metronidazole in the treatment of GAgP.
Key words: Aggressive periodontitis, amoxicillin, metronidazole, moxifloxacin, nonsurgical periodontal debride-
ment. 
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Introduction
Aggressive periodontitis (AgP) is an inflammatory pe-
riodontal disease, which is complex, multifactorial, and 
destructive. 
AgP has been treated like other forms of periodonti-
tis. The established treatment of periodontitis involves 
cause-related therapy, which includes: maintenance of 
oral hygiene, scaling and root planing (SRP), and surge-
ries of affected sites. Contrary to gingivitis and chronic 
periodontitis, mechanical non-surgical treatment does 
not always provide expected results in the treatment of 
AgP. In these cases, antibiotics may be used as an adjunct 
to treatment for eliminating or reducing the number of 
specific microorganisms and improving clinical parame-
ters when compared with SRP alone (1-4). The American 
Academy of Periodontology (AAP) and the European 
Federation of Periodontology (EFP) were reported that 
patients with GAgP may have benefit from the adjunctive 
systemic administration of antibiotics (1,5,6). 
Amoxicillin is a moderate spectrum; bacteriolytic 
β-lactam antibiotic, and metronidazole is active against 
anaerobic bacteria. SRP combination with metronidazole 
and amoxicillin therapy was found to be more effective 
in suppressing P.g. and eradication of A.a. and preventing 
re-colonization of A.a. because of the synergistic effect 
of this combination and their wide spectrum of activity. 
It was found to be superior to azithromycin, doxycycline, 
and metronidazole in the treatment of GAgP.
Moxiflocaxin is a fourth generation fluoroquinolone an-
tibiotic and exhibits good tissue penetration and high 
oral bioavailability. It has improved activity against Gr 
(-), aerobic and anaerobes and has good activity against 
putative periodontal pathogens located within biofilm 
or intracellulary (7). 
To the best of our knowledge, there is no study that eva-
luates the effect of moxifloxacin adjunct to SRP in the 
treatment of GAgP.
The aim of this study was to evaluate the impact of ad-
junctive systemic moxifloxacin; compared to the use of 
adjunctive systemic amoxicillin and metronidazole during 
full-mouth SRP based on the success of the treatment of 
patients with GAgP along with a 6-month follow-up. 
Material and Methods
This study was a single-center, randomized, parallel-
design clinical trial with 6 month follow-up. The study 
protocol was approved by the Ethics Committee of the 
Medical Faculty of Kocaeli University (KOU KAEK 
5/9). This clinical trial is registered; the identifier num-
ber is NCT02223702 (www.clinicaltrials.gov). The 
study protocol explained to the patients. From patients 
who willing to participate to the study, written informed 
consent was obtained and included the study.
The periodontal diagnosis of subjects with GAgP was 
performed according to the 1999 International World 
Workshop for a Classification of Periodontal Diseases 
and Conditions. Patients were included if they were 
between 18 and 35 years of age and otherwise healthy. 
Subjects were excluded if they had any known systemic 
diseases or conditions that can/could influence the pe-
riodontal status, allergies to quinolones, penicillin or 
metronidazole, a history of antibiotic therapy, or perio-
dontal treatment within the preceding six months.
- Periodontal Examination
The full-mouth clinical periodontal measurements were 
recorded at 6 sites per tooth, including plaque index 
(PI), gingival index (GI), probing depth (PD), bleeding 
on probing (BOP) and clinical attachment loss (CAL). 
- Nonsurgical treatment
Prior to treatment, all subjects had gone through moti-
vation sessions for oral hygiene. Following periodontal 
measurements, full-mouth supragingival scaling using 
an ultrasonic scaler  and polishing was performed. A 
toothbrush, toothpaste and an interproximal toothbrush 
were provided to all subjects. One week later, the pa-
tients were examined for plaque accumulation and oral 
hygiene. The patients who cannot maintain proper oral 
hygiene were excluded from the study. Only 39 patients 
fulfilled the qualification criteria for enrollment for the 
present study.
Subjects were randomly assigned to receive one of the 
two treatment groups. The moxifloxacin (MXF) group 
received SRP and adjunctive systemic antibiotic, 400 
mg MXF (1x1, 7 days). The amoxicillin and metronida-
zole (AMX+MET) group received a combination of 
500 mg of amoxicillin and 500 mg metronidazole (3x1, 
7 days). The subjects were instructed to take the first 
dose of the antibiotics in the morning of the first ses-
sion. SRP were performed during 2 consecutive days in 
24-h under the local anesthesia. On each day, SRP were 
performed in 2 quadrants using ultrasonic scalers and 
manual instruments. The endpoint of SRP was a tactile, 
smooth root surface.
Patients used a 0.2% chlorhexidine digluconate rinse 
(2x1, 30 days) and brushed their teeth by toothbrushes 
and interproximal toothbrushes  twice a day. Patients 
asked to report any adverse events and side effects of 
the antimicrobial agents.
Subjects were monitored one week after the second SRP 
session. At this session, antibiotic intake and adverse 
events were questioned; oral hygiene was controlled. 
Subjects were screened at 1, 3 and 6 months after comple-
tion of SRP. During these sessions, periodontal indices 
and any medical history change; especially whether an-
tibiotic therapy had been prescribed for any reason was 
recorded. 
- Statistical Analysis
The reliability of continuous variables was expressed as 
the SD of the differences divided by 2. According to the 
reliability analysis for PD and CAL, the measurement 
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errors were 0.13 and 0.11, respectively. Cohen’s K was 
employed to describe the reliability of discrete PI and GI 
values. Based on the duplicate measurements, the kappa 
values of PI and GI were 0.76±0.04 and 0.86±0.05, res-
pectively.
Depending on the normality in the distribution of the 
clinical parameters, Mann-Whitney-U and indepen-
dent T-test were used for the differences between the 
groups. The changes in clinical parameters among dif-
ferent evaluation periods for each group were analyzed 
using Friedman and the repeated measure ANOVA test, 
where applicable. Additionally, when the p value from 
the Friedman test was statistically significant, multiple 
comparison tests were used to ascertain which evalua-
tion time point differed from the others.
Results
Figure 1 shows flow diagram of the present study. A 
total of 39 subjects were enrolled into the present study; 
baseline demographic variables and clinical periodontal 
parameters are shown in table 1.
Fig. 1. Flow diagram of the study according to CONSORT 2010.
A total of 12.000 subjects applied to dental school 
60 GAgP patients examined for eligibility  
Excluded  (n= 21)
X   Not meeting inclusion criteria, 
declined to participate and other reasons 
Lost to follow-up (n=2)
x Antibiotic intake (n= 1) 
x Did not return to follow-up (n=1)
Allocated to intervention (n= 19)
  Received SRP +  
  400 mg Moxiflocaxin (7 days, 1X1) 
Lost to follow-up (n=1)
x Moved to another city  (n= 1) 
Allocated to intervention (n= 20)
  Received SRP +  
  500 mg Amoxicillin (7 days, 3X1) +  
  500 mg Metronidazole (7days, 3X1) 
1st Month Follow-Up 
Allocation Randomized (n= 39)
Enrollment
Lost to follow-up (n=2)
x Did not return to follow-up (n=2) 
No lost to follow-up No lost to follow-up 
3rd Month Follow-Up 
120 subjects screened as GAgP 
Analysed  (n=15) Analysed  (n=19)
6th Month Follow-Up 
Analysis
No lost to follow-up 
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While one subject from AMX+MET group was with-
drawn at 1st month visit, four subjects from MXF group 
were withdrawn at 1st and 6th month visits. Fifteen sub-
jects in the MXF group (7 males and 9 females; mean 
age, 30.32±3.81 years; range, 24-35 yrs) and 19 subjects 
in the AMX+MET group (9 males and 10 females; mean 
age, 30.95±3.66 yrs; range, 25-35 years) completed the 
study (Table 1). There were no significant differences 
between the groups at any point related to age, gender, 
and smoking status. (p>0.05) (Table 1).
Each subject of the MXF group received 7 tablets of 
MXF 400 mg and each subject of the AMX+MET group 
received a total of 21 tablets of AMX 500 mg and MET 
500 mg.
Table 1. Demographic and clinical characteristics of the GAgP patients.
* Mean ± SD, NS=Difference between groups is not statistically significant (p-value>0.05).
Baseline Parameters MXF Group (N=19) 
AMX + MET Group 
(N=20) p-value
Age (mean years ± SD) 
(min-max)
30.95 ± 3.66 
(24 – 35) 
30.22 ± 3.90  
(25 – 35) NS 
Female / Male (n) 9/10 10/10 NS 
Smokers (n) 5 (26%) 6 (30%) NS 
Plaque Index*  2.39 ± 0.39 2.45 ± 0.42 NS 
Gingival Index* 1.41 ± 0.22 1.25 ± 0.29 NS 
Probing Depth* (mm) 4.19 ± 0.62 4.57 ± 1.08 NS 
Bleeding on Probing* (%) 66 ± 0.16 67 ± 0.17 NS 
Clinical Attachment Loss* (mm) 4.94 ± 0.81 5.31 ±1.14 NS 
    
Demographic features of AgP 
patients completing the study 
MXF Group 
(n=15) 
AMX + MET Group 
(n=19) p-value
Age* (mean years ± SD)  
(min-max)
30.32 ± 3.81 
(24 - 35) 
30.95 ± 3.66 
(25 - 35) 
NS 
Female / Male (n) 9/7 10/9 NS 
Smokers (n, %) 4,  % 26.6 8, % 42.1 NS 
While none of the test subjects reported any adverse 
event associated with MXF, two subjects reported a 
stomachache and one subject reported gastrointestinal 
problems related to AMX+MET intake.
Both groups demonstrated statistically a significant decrease 
in all clinical periodontal parameters at the end of the 1st, 
3rd and 6th months compared to the baseline (PI; p<0.001 
and GI, PD, BOP, CAL, p<0.01, Tables 2 and 3). 
There were no significant differences between the 1st 
and 3rd, and 3rd and 6th month in the groups whereas 
none of the periodontal parameters showed intergroup 
differences in any time points (p>0.01), except GI at 6th 
months (p<0.05) (Tables 2 and 3)
As shown in table 3, both groups demonstrated statisti-
cally a significant decrease in PD and CAL at the 1st, 3rd 
and 6th month compared to the baseline (p<0.01). While 
the greatest reduction in the mean PD was seen at the 
3rd month, compared to the baseline in both groups 
(p<0.01), but this difference was not statistically signifi-
cant compared to the 1st and the 6th month. The great-
est reduction in the mean CAL was seen during the 1st 
month in the MXF group and in the 3rd month in the 
AMX+MET group compared to the baseline (p<0.01). 
However, these differences were not significant com-
pared to other follow-up visits. No difference was found 
between groups at any point in 6 months.  
The mean PD reduction and the mean clinical attachment 
gain at the 6th month were 1.17±0.16 mm and 0.64±0.12 
mm, respectively, in MXF group and 1.42±0.41 and 
0.70±0.20 mm, respectively, in AMX+MET group. No 
significant differences were observed between groups. 
The changes as percentage in PD and CAL are also 
evaluated under 3 categories, as <4 mm (shallow), 4-6 
mm (moderate) and >6 mm (severe) (8). Percentage 
of PD was increased to 27.56% in pockets initially <4 
mm in MXF group and 33.61% in AMX+MET group 
(Table 4), and no difference was seen between groups. 
Percentage of PD was decreased by 14.99% in pockets 
initially 4-6 mm, 12.65 in pockets initially >6 mm in 
MXF group, and 14.75% and 17.80% % in AMX+MET 
group, respectively (Table 4) and no differences were 
seen between groups.
Percentage of CAL was increased by 46.70% in 
pockets initially <4 mm in MXF group and by 42.10% 
in AMX+MET group (Table 5), and there was no sig-
nificant difference between the groups. Percentage of 
CAL was decreased by 26.70% in CAL initially >6 mm, 
20.00% in CAL initially 4-6 mm in MXF group, and 
26.30% and 15.8% in AMX+MET group, respectively. 
No differences were observed between the groups; 
however, there was a significant difference between the 
1st and the 3rd month in CAL 4-6 mm category in MXF 
group (p<0.05).  
There were no differences between groups in any ca-
tegories at any time.
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MXF Group    AMX + MET Group 
PI Baseline 2.39 (2.25 - 2.48) 
   2.53 
(2.33 - 2.71) 
1m 0.07 (0 - 0.11) 
  a   0.07 
(0 - 0.21) 
d   
3m 0.22 (0.08 - 0.34) 
    † b  0.27 
(0 - 0.41) 
      † e  
6m 0.22 (0.12 - 0.37) 
     †  c 0.18 
(0.07 - 0.34) 
      †  f 
GI Baseline 1.38 (1.26 - 1.48) 
   1.27 
(1 - 1.54) 
1m 0.14 (0 - 0.19) 
  a   0.028 
(0 - 0.14) 
d   
3m 0.14 (0 - 0.19) 
       † b  0.03 
(0 - 0.14) 
      † e  
6m 0.35  (0 - 0.67) 
       † 
  * 
 c 0.14 
(0.06 - 0.3) 
      †  f 
BOP Baseline 0.65 (0.52 - 0.77) 
   0.72 
(0.56 - 0.8) 
1m 0.11 (0.1 - 0.2) 
  a   0.14 
(0.06 - 0.21) 
d   
3m 0.24 (0.17 - 0.29) 
      †       b  0.16 
(0.1 - 0.22) 
       † e  
6m 0.27 (0.14 - 0.36) 
      †  c 0.14 
(0.1 - 0.2) 
      †  f 
Table 2. Median (25th-75th percentiles) values for plaque index (PI), gingival index (GI) and bleeding on probing (BOP) of 
MXF and AMX+MET groups for each recalls. 
a: Significant difference between baseline and 1m (p<0.01) for MXF group
b: Significant difference between baseline and 3m (p<0.01) ) for MXF group
c: Significant difference between baseline and 6m (p<0.01) ) for MXF group
*: Significant difference between groups for GI at 6m (p<0.05)
d: Significant difference between baseline and 1m (p<0.01) for AMX + MET group
e: Significant difference between baseline and 3m (p<0.01) for AMX + MET group
f: Significant difference between baseline and 6m (p<0.01) for AMX + MET group
†: No significant difference between 1st and 3rd months and 3rd and 6th months in and between AMX + MET and MXF 
groups.
MXF Group     AMX + MET Group 
PD Baseline 4.18 ±0.62  (2.98 - 5.45) 
4,57 ± 1.08 
(2.88 - 5.21) 
   
1m 2.91±0.38 (2.4 - 4.02) a    
3.12 ±0.68 
(1.91 - 4.86) d   
3m 2.79 ±0.33 (2.31 - 3.7)     † b   
3.11±0.6 
(2.15 - 4.82)   † e  
6m 3.01 ±0.46 (2.53 - 4.17 
     
†  c  
3.15±0.67 
(2.35 - 5.44)    †  f 
          
CAL Baseline 4.94±0.81 (3.76 - 6.56) 
   5.03±1.14 
(3.65 - 8.87) 
 1m 4.14±0.87 (2.9 - 6.08) a    
4.37±0.87 
(3.06 - 6.44) 
d
 3m 3.98±0.82 (3.07 - 5.72)   † b   
4.41±0.93 
(3.27 - 7.01)    † e  
 6m 4.3±0.93 (2.96 - 6.56)   †  c  
4.33±0.94 
(3.23 - 7.02)     †  f 
Table 3. Mean ± standard deviation (minimum-maximum) values for probing depth (PD) and clinical attachment loss 
(CAL) of each recall.
a: Significant difference between baseline and 1m (p<0.01) for MXF group
b: Significant difference between baseline and 3m (p<0.01) ) for MXF group
c: Significant difference between baseline and 6m (p<0.01) ) for MXF group
d: Significant difference between baseline and 1m (p<0.01) for AMX + MET group
e: Significant difference between baseline and 3m (p<0.01) for AMX + MET group
f: Significant difference between baseline and 6m (p<0.01) for AMX + MET group
†: No significant difference between 1st and 3rd months and 3rd and 6th months in and between AMX + MET and MXF 
groups.
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Discussion
To our knowledge, this study was the first clinical study, 
which evaluates the effects of systemic moxifloxacin 
compared to the adjunctive systemic amoxicillin and 
metronidazole as an adjunct to nonsurgical treatment in 
the treatment of patients with GAgP. On the basis of 
the present findings, it can be concluded that adjunctive 
moxifloxacin provides comparable clinical improve-
ment to that of the combination of amoxicillin and me-
tronidazole in the treatment of GAgP. 
All periodontal clinical parameters were dramatically 
decreased in both groups at the 1st month compared to 
the baseline and all patients maintained good hygiene 
and post-treatment follow-ups. In the present study, 
although no effort was made to control the smoking; 
smokers were equally distributed between groups and 
the results did not change (data not shown). 
Management of AgP is always challenging for clinicians 
since every case is unique and there are no established 
treatment guidelines or protocols. In the treatment of 
AgP, a number of antimicrobial regimens have been in-
vestigated, which aim to potentiating the effects of SRP. 
It was shown that nonsurgical treatment together with 
systemic use of antibiotics in AgP yields better clinical 
results and less surgery needs (9-11) when comparing 
nonsurgical treatment alone (1,2,12). 















PD <4 mm 
(Shallow) 
MXF




48.33 81.04  32.71** 82.70  34.37** 81.94  33.61** 
PD 4-6 mm 
(Moderate) 
MXF




29.37 15.28 14.09* 14.25 15.12* 14.62 14.75* 
PD > 6 mm 
(Severe) 
MXF




21.24 2.40 18.84* 3.05 18.19* 3.44 17.80* 
Table 4. Alterations of probing depth (PD) (a) and clinical attachment loss (CAL) (b) categories as percentage among recall periods for the 
groups. (a) Probing depth (PD) categories (%).
* : Significant difference between baseline and 1st m, 3rd m and 6th m (p< 0.05)
** : Significant difference between baseline and 1st  m, 3rd m and 6th m (p< 0.01)




















CAL <4 mm 
MXF Group 13.30 53.30 40.00*** 73.30 60.00*** 60.00 46.70*** 
AMX + MET 
Group 5.30 36.80 31.50** 42.10 36.80** 47.40 42.10** 
CAL 4-6 mm 
MXF Group 46.70 33.30a 13.40* 20 26.70* 26.70 20.00* 
AMX + MET 
Group 47.40 42.10 5.30 36.80 10.60 31.60 15.80* 
CAL > 6 mm 
MXF Group 40.00 13.30 26.70** 6.70 13.30* 13.30 26.70** 
AMX + MET 
Group 47.40 21.10 26.30** 21.10 26.30** 21.10 26.30** 
Table 5. Alterations of probing depth (PD) (a) and clinical attachment loss (CAL) (b) categories as percentage among recall periods for the 
groups. (b) Clinical attachment loss (CAL) categories (%).
*: Significant difference between baseline and 1st m, 3rd m and 6th m (p< 0.05)
**: Significant difference between baseline and 1st m, 3rd m and 6th m (p< 0.01)
***: Significant difference between baseline and 1st m, 3rd m and 6th m (p< 0.001)
a: Significant difference between 1st and 3rd  months (p< 0.05)
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In the present study, there were no differences in, and 
between the groups at any time. Then, we categorized 
the parameters as slight, moderate, and severe (Tables 
4 and 5). There was also no difference between the 
groups. However, when each patient was evaluated as 
a separate entity, it was found that the alterations in the 
frequencies of CAL categories were significantly diffe-
rent at all times in both groups.
The mean for the full-mouth PD reduction and the 
clinical attachment gain were better (13) or comparable 
(4,8,10-12) to those reported in patients with GAgP at 
the 6th month. However, it is not convenient to make di-
rect comparisons between the studies due to discrepan-
cies among the study methodologies.  
In the treatment of AgP, different antibiotic regimens, 
length of antibiotic therapy, timing of the administra-
tion, different dosages, evaluation parameters and clini-
cal outcome assessments have been studied, however 
there is no consensus or definite conclusion, yet (2,9). 
As stated by Mombelli et al. (9); “Useful antibiotic 
regimes for distinct clinical or microbiological condi-
tions could not be clearly identified based on available 
evidence,” “The optimal timing for antibiotic admi-
nistration is still controversial”, hence, “There are no 
evidence based guidelines for the use of systemically 
administered antibiotics (14).” 
Different amoxicillin and metronidazole dosages used 
by the researchers in the studies. In the present study, 
500 mg of both amoxicillin and metronidazole, three 
times a day were prescribed for each person to reach a 
minimum effective concentration of antibiotics in gin-
gival crevicular fluid and blood. 
The timing of the antibiotic regime is still unclear, ho-
wever, based on studies and reviews, Consensus Report 
of the Sixth European Workshop on Periodontology 
concluded that antibiotic intake should start on the day 
of non-surgical treatment (15). 
Duration of the antibiotic regime also changes between 
the studies. Nevertheless, to date, there is no clear state-
ment about the duration of the antibiotic use. It is con-
cluded that the SRP should be carried out in the shortest 
time possible, preferably less than 7 days in AgP (15,16). 
Hence, in the present study, antibiotic administration 
was started after the initial periodontal treatment; in the 
morning of the same day of SRP, and the treatment was 
completed in 24 hours, using 7-day systemic antibiotic 
regimes for both groups.
Moxifloxacin is a fourth-generation fluoroquinolone 
with a broad spectrum of activity against microorga-
nisms and pathogens with resistance to penicillin, ma-
crolides, and tetracyclines. It contains a C-8 methoxy 
substitute that increases bactericidal activity and there 
is a marked the time-kill kinetics and post-antibiotic ef-
fect (17). Moxifloxacin is effective and generally very 
well tolerated by patients and the reported side effects 
are very low. It is expected that the patient’s compliance 
might be enhanced since prescribing a single-dose per 
day is possible, due to its pharmacokinetics. 
Efficacy of moxifloxacin in dental research is mostly 
evaluated in the treatment of odontogenic abscesses or 
infiltrates and promising in vitro activity against odon-
togenic pathogens was revealed over amoxicillin-cla-
vulanic acid, clindamycine, doxycycline and penicillin. 
Moxifloxacin has a favorable bacterial activity against 
putative periodontal pathogens including P.g., A.a. and 
T. forsythia (7,18). In an in vitro study, the activity of 
moxifloxacin was compared with ofloxacin and doxy-
cycline against single-species biofilms of two P.g. and 
two A.a. strains and a multispecies biofilm consisting 
of 12 species and a topical formulation of moxifloxacin 
as an adjunct to mechanical treatment is suggested (19). 
The good penetration of moxifloxacin into soft and hard 
tissues in Wistar rats was also shown (20). Moxifloxa-
cin was found to be comparable to that of amoxicillin-
clavulanate however superior to those of clindamisin, 
metronidazole, doxycycline or penicillin (21-23). 
In a study by Müller et al. (7), it showed that A.a. strains 
were highly susceptible to fluoroquinolones, ciprofloxa-
cin and moxifloxacin. Some of the adjunctive antibiotics 
are secreted in saliva in insufficient concentrations to 
inhibit A.a. Moxifloxacin seems to be secreted in saliva 
at higher levels than in plasma and may also concentrate 
at the site of infection since it penetrates polymorpho-
nuclear granulocytes and epithelial cells (7). 
In the present study, to potentiate the outcomes of non-
surgical periodontal treatment, SRP performed in 24-h 
period in combination with chlorhexidine digluconate 
mouthrinse and systemically administered antibio tics 
by reducing the number of periodontopathogen not 
only from periodontal pockets but also from their other 
habitats such as saliva, the tongue, and by retarding re-
colonization of the bacteria. AgP patients might have 
benefits from this approach. 
The present study is the use of only one type of anti-
biotic with less amounts of tablets; instead of two dif-
ferent types of antibiotics with a lot more tablets taken. 
This treatment alternative might cause fewer side ef-
fects with similar clinical outcomes and enhance patient 
compliance. In the contrary to previous reports, three 
patients who use AMX+MET, reported adverse effects 
(4,12). However, other studies are reported varying side 
effects related to AMX+MET (11,24,25). There is no re-
port regarding adverse effects of moxifloxacin in perio-
dontal treatment.  
One would consider why a control group (without anti-
biotics) did not think to be included in the present study. 
This might be a one of the limitations of the present 
study. However, as we summarized and discussed in 
this section, the antibiotic used as an adjunct to SRP 
is approved with research and accepted with consensus 
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reports released by EFP and AAP in the treatment of 
GAgP. Hence, we thought that it would not be ethical 
to monitor the nonsurgical treatment of patients with 
GAgP without an adjunct antibiotic. While the effect 
of adjunctive AMX+MET in the treatment of GAgP 
is well defined (4,11,12,26), antibiotic combination of 
AMX+MET was considered as control. 
Another limitation of the present study would be the 
lack of microbiological evaluation. There are two ma-
jor indications for microbiological testing in Periodon-
tology; first, to detect subgingival microbial flora for 
accurate diagnosis. It was stated that all patients with 
GAgP may not have an identical and specific microbial 
profile related with GAgP (27). Moreover, subgingival 
microbial factors in GAgP do not seem different from 
patients with chronic periodontitis. Prevalence and be-
haviors of periodontopathogens may not adapt to diffe-
rent populations and ethnicities (28,29). It was reported 
that A.a.-positive patients had no specific benefit from 
AMX+MET (24), which means combinations or spe-
cific antibiotic regimens may not work in all cases (14). 
On the other hand, Heller et al. (26) emphasized inter-
individual varieties of periodontopathogens in the sub-
gingival microbial flora of patients with GAgP and con-
cluded that not all GAgP patients had greater microbial 
benefits from AMX+MET combination. The patients 
had species associated with GAgP were more affected 
from this combination.  
Second, was to determine the antibiotic susceptibility/
resistance of periodontopathogenic profiles for proper 
treatment. It was noted that European and South Ameri-
can countries have significant differences in their an-
tibiotic susceptibility profiles of periodontal bacteria 
(30). van Winkelhoff et al. (30) concluded that “it may 
not be possible to develop uniform protocols in the ad-
ministration of antibiotics and in the treatment of severe 
type of periodontitis. More accurate approach might be 
as follows: to analyze the subgingival microflora, to 
characterize periodontopathogens, to decide for pres-
cribing antimicrobial regime or not, and to test that an-
timicrobial drugs for bacterial resistance and suscepti-
bility. Otherwise, antibiotics are not always clinically 
effective. Nevertheless, in most of the studies, bacterial 
resistance and susceptibility are disregarded and bac-
terial counts are reported; following administration of 
any antimicrobial regimes. The most optimal antibiotic 
regime would be determined with antibiotic susceptibi-
lity testing. On the other hand, different microbiology 
laboratory set-ups, hence different test reports, complex 
microbial flora, empiric and the misuse of antibiotics 
may limit to use of microbial test. 
Having taken together all the provided data from other 
studies, it is difficult to compare and conclude adjunc-
tive benefits of antimicrobial treatments due to both the 
paucity of randomized controlled studies and the dif-
ferent methodologies of the studies. Moreover, suppres-
sion/eradication of targeted microorganisms does not 
mean to achieve clinical efficacy (9).
Conclusions
Within the limitation of the present study, we conclude 
that: although both antibiotic regimes together with non-
surgical treatment provided similar and favorable end re-
sults at 6 months, moxifloxacin use could be preferred by 
both dentists and the patients due to compliance because 
of the reduced number of tablets and the single-dose per 
day, as well as in patients with allergies, intolerance, or 
lack of response to amoxicillin and metronidazole. Ne-
vertheless, antimicrobial treatment should be based on 
individual characteristics of the patients.
Further researches may involve individual risk assess-
ments, and individual treatment protocols.
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